Australia · Delayed Price · Currency is AUD Australian Clinical Labs Earnings Call Transcripts
Fiscal Year 2026
-
Underlying profitability and margins improved despite a 1% revenue decline, driven by operational discipline, digitalization, and portfolio optimization. Guidance anticipates H2 market recovery, with ongoing share buybacks and cost mitigation plans for wage increases.
Fiscal Year 2025
-
The AGM highlighted strong financial growth, strategic expansion, and operational improvements, with $44 million returned to shareholders. Despite a second strike on the Remuneration Report, all director re-elections were supported, and a new share buyback was announced.
-
Revenue grew 6.4% to $741.3M with EBIT up 8.7% and strong cash flow, despite market softness and fee cuts. FY 2026 guidance anticipates continued margin discipline, digital billing, and operational efficiencies, with $8M EBIT uplift expected in FY 2027.
-
Revenue grew 9.5% year-over-year to AUD 369 million, with underlying EBIT up 17% and strong cash flow. Guidance for FY25 EBIT is reaffirmed at AUD 65–73 million, with margin improvement expected in H2. Dividend of AUD 3.50 per share declared.
Fiscal Year 2024
-
The AGM highlighted stable revenue and profit despite a sharp drop in COVID-related income, with operational improvements and a strong balance sheet supporting dividends and a share buyback. Strategic focus includes network expansion, new genetic tests, and ESG initiatives.
-
FY24 saw stable revenue as non-COVID growth offset a sharp COVID revenue decline, with strong cash flow, margin recovery in H2, and a robust balance sheet. FY25 guidance anticipates 4–8% revenue growth, higher EBIT, and continued operational improvements.